阿托伐他汀联合低分子肝素治疗慢性阻塞性肺疾病急性加重期疗效观察

目的 探讨阿托伐他汀联合低分子肝素治疗慢性阻塞性肺疾病急性加重期的疗效.方法 将64例慢性阻塞性肺疾病急性加重期的患者随机分为治疗组34例,对照组30例.对照组采用常规治疗,治疗组在常规治疗的基础上加用阿托伐他汀和低分子肝素治疗.2周为1个疗程.治疗前后两组同步检测凝血酶原时间（PT）、纤维蛋白原（FIB）、动脉血气、超敏C-反应蛋白（hs-CRP）和测定吸入支气管扩张剂后肺功能相关指标.结果 治疗组治疗后较治疗前FIB、hs-CRP、PaCO2显著降低（P＜0.01）,PT、PaO2、SO2%和FEV1/FVC显著升高（P＜0.05）;对照组治疗前后PT、FIB、hs-CRP各项指标略有改善,但差异无统计学意义（P＞0.05）;肺功（FEV1/FVC）、动脉血气（PaO2、PaCO2和SO2%）有改善（P＜0.05）;治疗后治疗组与对照组之间的检测指标比较,PT、FIB、hs-CRP、PaCO2、PaO2、SO2%和FEV1/FVC均有差异有统计学意义（P＜0.05或P＜0.01）.结论 慢性阻塞性肺疾病急性加重期的患者在常规治疗的基础上加用阿托伐他汀和低分子肝素降低血液粘度,抑制肺血管炎症反应,改善肺功能,进而延缓COPD的进程.

Atorvastatin Combined with Low Molecular Weight Heparin in Treatment of Chronic Obstructive Pulmonary Disease in Acute Exacerbation Period

Objective To explore the effect of Atorvastatin Combined with low molecular weight heparin in treatment of acute ex- acerbations of chronic obstructive pulmonary disease. Methods Randomly divide 64 cases of acute exacerbation of chronic obstructive pulmonary disease for 34 cases in the treatment group, 30 cases in the control group. The control group conventional treatment, the treatment group on the basis of conventional therapy plus atorvastatin and low molecular weight heparin in the treatment of 2 weeks for 1 courses. Before and after treatment in the two groups of synchronous detection of prothrombin time （PT） , fibrinogen （ FIB ） , arterial blood gas, high sensitive C- reactive protein（ hs- CRP）and the correlative indexes of pulmonary function after inhaling broncbodila- tots. Results The treatment group after treatment than before treatment FIB ,hs - CRP, PaCO2 decreased significantly （ P 〈 0.01 ）, PT, PaO2,SO2 % and FEV1/FVC were significantly increased （P 〈 0. 05 ） ;the control group before and after treatment PT, FIB, hs -ClIP indicators improved slightly,but the difference was not statistically significant（ P 〉 0.05 ） ;pulmonary function（ FEV1/ FVC） ,arterial blood gas（ PaO2, PaCO2 and SO2 % ）have improved（ P 〈 0.05 ） ;comparative indices between group and control group after treatment, there was statistical significance in PT, FIB, hs - CRP, PaCO2 , PaO2 , SO2 % and FEV1/FVC were significantly different （ P 〈 0.05 or P 〈 0. 01 ）. Conclusion Patients treated with atorvastatin and low molecular weight heparin reduces blood viscosity on the basis of con- ventional treatment of acute exacerbation of chronic obstructive pulmonary disease ,inhibited pulmonary vascular inflammatory reaction, improve lung function, and delay the progress of COPD.